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Abstract
Background: Few assessments of the costs and benefits of reducing acute cardiorespiratory
morbidity related to air pollution have employed a comprehensive, explicit approach to capturing
the full societal value of reduced morbidity.
Methods: We used empirical data on the duration and severity of episodes of cardiorespiratory
disease as inputs to complementary models of cost of treatment, lost productivity, and willingness
to pay to avoid acute cardiorespiratory morbidity outcomes linked to air pollution in
epidemiological studies. A Monte Carlo estimation procedure was utilized to propagate uncertainty
in key inputs and model parameters.
Results: Valuation estimates ranged from $13 (1997, Canadian) (95% confidence interval, $0–28)
for avoidance of an acute respiratory symptom day to $5,200 ($4,000–$6,400) for avoidance of a
cardiac hospital admission. Cost of treatment accounted for the majority of the overall value of
cardiac and respiratory hospital admissions as well as cardiac emergency department visits, while
lost productivity generally represented a small proportion of overall value. Valuation estimates for
days of restricted activity, asthma symptoms and acute respiratory symptoms were sensitive to
alternative assumptions about level of activity restriction. As an example of the application of these
values, we estimated that the observed decrease in particulate sulfate concentrations in Toronto
between 1984 and 1999 resulted in annual benefits of $1.4 million (95% confidence interval $0.91–
1.8 million) in relation to reduced emergency department visits and hospital admissions for
cardiorespiratory disease.
Conclusion: Our approach to estimating the value of avoiding a range of acute morbidity effects
of air pollution addresses a number of limitations of the current literature, and is applicable to
future assessments of the benefits of improving air quality.
Background
Numerous assessments have been conducted around the
world of the costs and/or benefits of interventions to im-
prove air quality [1–7]. Benefits assessments typically
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employ the damage function approach, consisting of esti-
mating changes in air pollution emissions and resultant
changes in ambient air quality; calculating the number of
avoided adverse health and environmental outcomes us-
ing concentration-response functions; and applying eco-
nomic value measures to avoided outcomes [8], often
extrapolating valuation estimates from the original con-
text in which data were collected [9]. The majority of ben-
efits generally derive from improved human health,
including both reduced mortality and morbidity. Benefits
of reduced mortality and chronic morbidity tend to dom-
inate these assessments, accounting for over 90 percent of
benefits in most instances [1,7]. Nonetheless, acute mor-
bidity is still viewed as an important component of the
broad public health burden associated with air pollution
[10], and benefits assessments will undoubtedly continue
to include acute morbidity effects. Thus, future assess-
ments will need to address deficiencies in past work deal-
ing with acute morbidity, including failure to consistently
employ a comprehensive, explicit approach to capturing
all components of the societal value of reduced morbidity
and differing levels of severity of symptoms and activity
restrictions.
In earlier analyses [3,5], consideration of morbidity effects
of air pollution was restricted to a limited range of symp-
toms and activity restrictions as observed in clinical and
epidemiological studies. These assessments, as well as
more recent ones [2], relied heavily on contingent valua-
tion studies [11–13] in which individual willingness to
pay (WTP) to avoid a variety of symptoms of varying du-
ration was evaluated. In more recent assessments, there
has been a greater reliance on cost of illness (COI) data,
comprising medical costs and lost production experi-
enced by society as a result of a health effect. However,
these measures represent at best a lower bound on the to-
tal societal value of avoiding these health outcomes [14],
since they reflect only one element of this value. In some
assessments, no adjustments have been made to correct
for this bias [6,7], while in others, empirical evidence
from studies which simultaneously measured COI and in-
dividual WTP have been used to derive adjustment factors
[1,4,15–17]. Such adjustments recognize deficiencies in
available estimates, but applying them uniformly to a va-
riety of cardiorespiratory conditions could introduce error
in benefits assessments. An additional issue is that most
previous assessments have relied heavily upon valuation
estimates derived from U.S. data, the applicability of
which outside the U.S. can be questioned.
In the present study, our objective was to estimate the
benefits of avoiding a variety of acute cardiorespiratory
morbidity outcomes which have been linked epidemio-
logically to air pollution, using complementary data on
COI and individual WTP. In contrast to the lack of a con-
sistent, comprehensive approach in earlier studies, partic-
ular features of our approach include application to all
outcomes of: a consistent conceptual model of the nature
of acute episodes of cardiorespiratory disease, including
differing levels of severity of symptoms and activity re-
strictions; a comprehensive valuation framework encom-
passing all aspects of the value of avoided morbidity and
a recognition of the perspective (societal versus individu-
al) from which primary data were collected; a common
source of inputs based on empirical data on the duration
and severity of episodes of cardiorespiratory disease; and
an estimation procedure which propagates uncertainty in
key inputs.
Methods
Conceptual model of acute cardiorespiratory morbidity
We identified several types of acute cardiorespiratory mor-
bidity which have been linked with air pollution in epide-
miological studies: respiratory and cardiac hospital
admissions and emergency department visits, restricted
activity days, asthma symptom days, and acute respiratory
symptom days [18–21]. Based on this literature, we iden-
tified asthma, chronic obstructive pulmonary disease
(COPD), respiratory infections, congestive heart failure,
cardiac dysrhythmias, and myocardial infarction/angina,
as well as mild non-specific respiratory symptoms, as the
principal conditions of interest [18–22].
As a general framework, we viewed these conditions as oc-
curring in the form of acute episodes superimposed upon
the underlying baseline health state. The extent to which
health status departed from its premorbid level could be
expected to vary during the course of the episode, so that
the episode of illness could be characterized as the sum of
several periods, each of which is associated with a given
decrement from baseline health status. Depending on the
nature of the morbidity outcome, these periods might in-
clude periods spent in or out of hospital, and in various
states of restriction of activity.
Valuation framework
Reduced morbidity due to cleaner ambient air represents
real economic value to individuals and society, measured
most appropriately in a welfare economic framework by
WTP to improve health or willingness to accept compen-
sation (WTA) to worsen it [23]. Measures such as quality-
or disability-adjusted life years (QALYs or DALYs) repre-
sent an alternative measure which generically reflects pref-
erences among health states involving loss of quality and/
or quantity of life [24]. However, experience with applica-
tion to acute effects of air pollution is limited [25], and
unlike dollar valuation of health outcomes, these meas-
ures do not permit direct comparisons to costs. WTP (and
WTA) are generally regarded as comprising several com-
ponents: expenditures related to medical treatment ofEnvironmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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adverse health effects, including costs of treatment as well
as related out of pocket expenditures (for example, for as-
sistance in completing usual unpaid chores that the indi-
vidual is unable to undertake as a result of ill health); the
dollar value of interruption in work duties, which can
range from decreased productivity to absence from the
workplace; expenditures to avert or mitigate future occur-
rences of the effect (eg. purchasing an air conditioning
unit as a means of reducing the chances of an asthma at-
tack associated with outdoor air pollution); and the dollar
value of pain and suffering, inconvenience, restrictions
and reduced enjoyment of leisure activities, anxiety about
the future, and concern and inconvenience to family
members and others [14]. The perspective of the analysis
(societal versus individual) is clearly an important consid-
eration, in that individual WTP will not reflect medical ex-
penditures and lost productivity where there is third party
payment of medical expenditures or paid sick leave
[8,14,26].
A comprehensive measure of the total value, from a soci-
etal perspective, of avoiding the acute cardio-respiratory
morbidity effects of air pollution can therefore be ex-
pressed as follows:
VT = VAE + VPS + VCOT + VLP   (1)
where,
VAE = value of reduced averting expenditures;
VPS = value of reduced pain and suffering;
VCOT = cost of treatment including reduced expenditures
on mitigation of the illness; and
VLP = value of lost productivity.
Sources of empirical data
We used empirical results from two recent studies in order
to generate estimates of VT. Both studies have been de-
scribed in detail elsewhere [27–29], but are summarized
briefly below.
In the first study, joint estimates were constructed of indi-
vidual WTP to reduce acute episodes of respiratory and
cardiovascular ill health based on graded-pairs and
choice-based stated preference survey responses among
399 randomly selected subjects in Toronto in 1997
[28,30]. The survey instrument employed health-state de-
scriptions based on the Quality of Well Being (QWB) in-
dex [31,32], with attributes comprising symptoms, motor
function, and ability to fulfill roles and expectations. The
scope of symptoms was selected to correspond to the car-
diorespiratory conditions of policy interest as described
above. Four levels of activity restriction were considered
(Table 1). The payment vehicle employed in this survey
was described as illness related costs not covered by the
government health system or a company insurance plan.
Because pre-testing revealed that respondents with and
without paid sick leave interpreted costs differently and
this led to ambiguity in interpretation of their WTP, re-
spondents were instructed to assume that they had paid
sick leave. By combining results from graded-pairs and
choice formats, the resulting estimates from this study are
more robust than estimates based on a single format. In
addition, relative to other studies in the WTP literature in
this area, estimates from this study were based on compre-
hensive multi-attribute health state descriptions which
ensured that key attributes were clearly and consistently
presented to respondents, for the wide range of symptoms
and severity levels covered in the study. Estimates from
this study were not systematically smaller or larger than
other literature and varied logically with duration and se-
verity of outcomes. However, given the payment vehicle
and the instructions regarding sick leave, we determined
that individual WTP estimated in this study would not re-
flect VLP or that portion of VCOT covered by public health
care system or third party insurance. We obtained these
data from the following study.
In the second study, data were collected prospectively on
individuals visiting emergency departments for cardiores-
piratory conditions, as part of an epidemiological study of
air pollution in Saint John, Canada between 1992 and
1996 [29,33]. A random sample of those agreeing to fol-
low-up was contacted two weeks after their visit and asked
to complete a structured telephone interview, in which in-
formation was collected on the duration of the disease ep-
isode which prompted their visit, disposition of their visit
(whether they were admitted or discharged), and the oc-
currence of various outcomes including restricted activity
days, days of missed work for the patient, parent, or other
care giver, health care utilization and illness-related ex-
penses, from the onset of their earliest symptoms until the
follow-up interview. Data were obtained for 1,772 indi-
viduals. Inpatient utilization data were also abstracted
from the clinical records of 393 randomly selected pa-
tients representing the same groups of cardiorespiratory
conditions, and cost of illness estimates were generated
which included fully allocated costs related to hospital
utilization and emergency department visits, as well as
costs of physician visits, medication use, equipment, and
out-of-pocket expenses [27]. We analyzed these data using
stepwise ordinary least squares regression. Selection of the
final multi-variate model was based on minimization of
Akaike's Information Criterion, the deviance penalized
for the number of parameters being estimated [34]. Com-
pared to other literature in this area, this study has the ad-
vantage of having been designed specifically toEnvironmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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prospectively quantify the broad quality of life impacts
and COI associated with episodes of cardiorespiratory dis-
ease, thus ensuring that the required data elements were
collected in a consistent, coordinated fashion. Cost analy-
sis was carried out in a manner consistent with current
methodological standards.
Estimation procedure
Based on these two studies, we calculated VT according to
Equation (1) as follows:
VPS + VAE = value from stated preference survey = VSP(SiA-
jDk) [28,30]
where Si, Aj, and Dk are the symptom complex, level of ac-
tivity restriction and duration of the illness episode re-
spectively (See [28] for details of the stated preference
valuation estimation procedure).
VCOT = f (diagnosis, duration, admission to critical care/non
critical care) (See results section below for model
specification);
VLP = DLP × WD
where DLP = duration of lost productivity in days; and WD
is the average daily wage for Canada in 1997 of $119.60
[35].
While recent recommendations note the friction cost
method as an alternative to the conventional human cap-
ital approach as potentially more accurately reflecting the
ability to replace disabled workers, thus minimizing soci-
etal productivity losses [26,36], we assumed that this was
not applicable in the current context, where illness epi-
sodes are of short duration. We did not attempt to value
productivity losses not resulting in lost time (i.e. reduced
work capacity), but we did capture time lost by parents
and other care givers.
In estimating VSP, we mapped symptoms and activity re-
strictions to the various health outcomes identifed in epi-
demiolgical and clinical studies as shown in Table 2.
Some outcomes were mapped to time periods both in and
out of hospital, in keeping with the expected natural his-
tory of an acute episode of cardiorespiratory morbidity.
Hospital admissions, for example, were considered to oc-
cur following a period over which symptoms and activity
restrictions began and worsened to the point that hospital
admission was required, and in turn, to be followed by a
period of recovery out of hospital before returning to the
baseline health state. Similarly, a proportion of emergen-
cy department visits was expected to result in eventual ad-
mission to hospital, with accompanying periods of
symptom onset and recovery. While, a priori, both asthma
symptom days and restricted activity days would include
days in hospital, on the basis of population-based data,
we estimated that the latter would account for a very small
Table 1: Description of symptoms and activity restrictions
Type of symptom/activity restriction Description
Upper Respiratory Stuffy or runny nose and sore throat.
Eye Irritation Eye irritation.
Asthma/COPDa Coughing, wheezing, shortness of breath.
Respiratory Infection Coughing or wheezing with fever, chills, aching all over.
Dysrhythmia Fluttering in chest and feeling light-headed
Congestive Heart Failure Shortness of breath, and swelling in ankles and feet.
Myocardial Infarction/Angina Pain in chest or arm.
Mild Limitationsb Can go to work, go to school, do housework, and participate in social or recreational activities, but have 
some physicial limitations (trouble bending, stooping, or doing vigorous activities because of this health 
condition).
Can go to work, go to school, do housework, but have some physical limitations (trouble bending, stoop-
ing, or doing vigorous activities), and cannot participate in social or recreational activities because of this 
health condition.
Housebound Cannot leave house, go to work, go to school, do housework, participate in social or recreational activities, 
and have some physical limitations (trouble bending, stooping, or doing vigorous activities) because of this 
health condition, but can care for self.
Help caring for Self Cannot leave house, go to work, go to school, do housework, participate in social or recreational activities, 
and need help caring for self (feeding, bathing, dressing, toilet).
In Hospital In hospital and need help caring for self (feeding, bathing, dressing, toilet)
achronic obstructive pulmonary disease bcollapsed into a single level corresponding to mild restrictions, for the purposes of the final model used to 
generate WTP estimates.Environmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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proportion of these less severe outcomes [1,22,37]. We
therefore did not map these outcomes to the in-hospital
level of activity restriction in generating our estimates.
Mapping of symptoms and levels of activity restrictions to
a given outcome was derived from empirical data from
our own emergency department study [29], and from a
population-based survey in Strasbourg, France on the
prevalence of minor respiratory symptoms [38]. Adjust-
ments were made, where applicable, to shift the distribu-
tion towards the mild end of the spectrum to reflect those
individuals who do not visit the emergency department
and whose symptoms are presumably less severe on
average.
The definitions of a number of health outcomes as exam-
ined in the air pollution epidemiology literature overlap
with one another (e.g. hospital admissions and emergen-
cy department visits, restricted activity days and acute res-
piratory symptoms), and this is reflected in our mapping
of these outcomes as shown in Table 2. This needs to be
considered in order to avoid double counting of benefits
among these health outcomes. Procedures have been sug-
gested to deal with this, for instance by subtracting occur-
rences of restricted activity days, from those related to
acute respiratory symptom days, prior to applying valua-
tion estimates [1].
All inputs to our estimates pertaining to the duration of
time in and out of hospital and of lost work days, and the
probability of requiring inpatient care at the ward or crit-
ical care level (Table 3), were derived from Stieb et al. [29].
Based on data from the U.S. National Health Interview
Survey, it was determined that work loss days comprise 21
percent of restricted activity days (standard error = 1.07%)
[39] and we applied this factor in estimating lost produc-
tivity costs associated with restricted activity days. This is
consistent with our mapping to the three levels of activity
restriction, where 20% fell into the housebound or need
help category. We assumed that 10 percent of asthma
symptom days and acute respiratory symptom days were
work loss days, based on the evidence described earlier.
Valuation estimates for cardiac and respiratory hospital
admissions and emergency department visits were calcu-
lated as the weighted average among specific cardiac and
respiratory conditions, with the weights based on the pro-
portion of hospital admissions and emergency depart-
ment visits accounted for by these conditions as reported
in Burnett et al. [22] and Stieb et al. [33].
We obtained Monte Carlo estimates for each morbidity
outcome by iteratively calculating its components (n =
1000), sampling from the observed distributions of mod-
el parameters, accounting for correlation among parame-
ters, and from the observed distributions of input values.
We report a central estimate which reflects model results
evaluated at the mean of input values, and a 95% confi-
dence interval bounded by the 2.5th and 97.5th percentiles
of the output distribution. Where demographic informa-
tion (age, education, income) and population health sta-
tus were employed as independent variables in calculating
Table 2: Mapping of symptoms and activity restrictions to health outcomes examined in epidemiological studies
ARSa RAD ASD REDV RHA CEDV CHA
Symptom Weightings (proportions)
Upper Respiratory 0.70 0.40
Eye irritation 0.30 0.15
Asthma/COPDb 0.15 1.00 0.44 0.60
Respiratory Infection 0.15 0.56 0.40
Dysrhythmia 0.05 0.23 0.13
Congestive Heart Failure 0.05 0.27 0.28
Myocardial Infarction/Angina 0.05 0.50 0.59
Activity Level Weightings (proportions)
Mild limitations 0.90 0.80 0.90 0.74 0.50 0.41 0.34
Housebound 0.10 0.15 0.10 0.14 0.09 0.08 0.06
Need help caring for self 0.05 0.05 0.03 0.03 0.02
In hospital 0.07 0.37 0.48 0.57
aARS = Acute Respiratory Symptom Day ASD = Asthma Symptom Day RAD = Restricted Activity Day REDV = Respiratory Emergency Depart-
ment Visit RHA = Respiratory Hospital Admission CEDV = Cardiac Emergency Department Visit CHA = Cardiac Hospital Admission bchronic 
obstructive pulmonary diseaseEnvironmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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stated-preference values, we conducted a sensitivity analy-
sis by employing both the values of these variables in the
original survey sample, as well as values based on the
1996 Canadian census and the 1996 National Population
Health Survey [40]. While specific subgroups of those ex-
periencing acute episodes of cardiorespiratory disease
may be more specifically susceptible to air pollution as a
trigger, and the severity of their disease episodes may dif-
fer from others, it is not possible to identify these groups
with confidence. In order to deal with uncertainty gener-
ated by this issue, we also conducted a sensitivity analysis
by varying the weight given to the least versus most severe
levels of activity restriction and symptoms. When compar-
ing our results with those from earlier studies, we convert-
ed values from other countries to the same year in
Canadian dollars using purchasing power parity [41].
They were adjusted to 1997 Canadian dollars using the
consumer price index for Canada for either all goods and
services (WTP based estimates) or for health care (cost of
treatment based estimates) [42]. While caution should be
exercised in transferring our estimates to other countries,
a similar procedure would be employed to do this, by ap-
plying the 1997 purchasing power parity between Canada
and the target country, and adjusting to the currency year
of interest using the country specific consumer price index
for all goods and services.
Results
Cost of treatment model
Results from our analysis of cost of treatment data are pre-
sented in Table 4. The largest coefficients were associated
with a diagnosis of congestive heart failure, and admis-
sion to critical care or non-critical care units. As reflected
in the interaction terms, critical-care (CC) costs for respi-
ratory infections (RI) and dysrhythmias (DYS) were
considerably lower (RI*CC and DYS*CC), as were non
critical-care (NCC) costs for asthma (AS*NCC). However,
non critical-care costs were higher for those with a diagno-
sis of myocardial infarction/angina (MIA*NCC). Dura-
tion was associated with a coefficient of approximately
$30 per day, but interaction terms essentially eliminated
this effect for some diagnoses.
Comprehensive valuation estimates
Results of our calculations of overall valuation for each
endpoint are presented in Table 5. Cost of treatment ac-
counted for the majority of the overall value in the case of
respiratory and cardiac hospital admissions, as well as car-
diac emergency department visits. In the case of respirato-
ry emergency department visits, cost of treatment
accounted for approximately forty-five percent of the
overall value. Lost productivity costs represented a small
proportion of the overall value, although the proportion
was greater for those endpoints which do not include a
cost of treatment component. For both hospital admis-
sions and emergency department visits, the overall value
was larger for cardiac compared to respiratory conditions.
Table 3: Inputs on duration and disposition for valuation calculations
Condition Admitted to: Number of days:
Critical Care Non-critical Care In Hospital Out of Hospital Lost Work
Percent Standard 
Error
Percent Standard 
Error
Mean Standard 
Error
Mean Standard 
Error
Mean Standard 
Error
Individuals admitted to hospital
Asthma 23.1% 4.8% 76.9% 4.8% 4.4 0.3 9.3 1.1 2.8 0.5
Chronic Obstructive 
Pulmonary Disease
0.0% 0.0% 100.0% 0.0% 7.9 0.7 9.4 2.6 0.8 0.6
Respiratory Infection 11.3% 3.4% 88.7% 3.4% 5.1 0.4 8.7 1.4 3.3 0.6
Congestive Heart Failure 12.9% 6.0% 87.1% 6.0% 7.2 0.7 8.9 2.4 1.2 0.6
Dysrhythmia 27.8% 10.6% 72.2% 10.6% 5.6 0.8 6.5 2.3 3.5 1.5
Myocardial infarction/angina 65.0% 3.8% 35.0% 3.8% 6.0 0.3 3.2 0.8 2.4 0.4
Individuals visiting emergency department
Asthma 2.6% 0.6% 8.5% 1.1% 0.6 0.1 12.9 0.5 1.2 0.1
Chronic Obstructive Pulmo-
nary Disease
0.0% 0.0% 38.5% 5.5% 3.9 0.6 14.0 1.7 0.7 0.3
Respiratory Infection 1.5% 0.5% 12.1% 1.3% 0.9 0.1 14.3 0.5 1.5 0.1
Congestive Heart Failure 8.9% 4.2% 60.0% 7.3% 4.8 0.7 8.5 1.8 0.8 0.4
Dysrhythmia 9.6% 4.1% 25.0% 6.0% 1.9 0.5 5.3 1.0 1.7 0.6
Myocardial infarction/angina 61.8% 3.8% 33.3% 3.7% 5.8 0.3 3.1 0.8 2.3 0.4Environmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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This is primarily attributable to the larger cost of treat-
ment for cardiac versus respiratory conditions. The ratio
between total value and COI (i.e. cost of treatment plus
lost productivity), ranged from 1.3 to 1.9 for those end-
points with a cost of treatment component, while the ratio
tended to be larger for those endpoints without a cost of
treatment component.
Results were not sensitive to choice of input values for de-
mographic and health status characteristics (original sur-
vey sample characteristics versus nationally representative
values for Canada). Sensitivity to the weighting given to
the levels of activity restriction differed among the end-
points. The total value of avoiding respiratory and cardiac
hospital admissions and emergency department visits var-
ied by less than 10% from base estimates when we varied
the weighting given to least versus most restrictive health
states based on empirical data as described earlier. Rela-
tive to the base values, the total value of avoiding restrict-
ed activity days and asthma symptom days was
respectively 54 and 57% lower and 65 and 104% higher
when weighting of the different health states was varied.
In all of the sensitivity analyses for restricted activity days
and asthma symptom days, point estimates fell within the
95% confidence intervals on the base case estimates.
However, the 95% confidence interval on the valuation
estimate for asthma symptom days with less severe activi-
ty restrictions overlapped 0. For acute respiratory symp-
tom days, valuation estimates for less and greater activity
restrictions were respectively $12 and $28, both of which
were within the 95% confidence interval on the base case
estimate. In all cases the 95% confidence interval over-
lapped 0.
Discussion
Our estimates of the value of avoiding a range of acute ef-
fects of air pollution on cardiorespiratory morbidity are
generally consistent with expectation in terms of the mag-
nitude of values relative to severity and duration. The
higher valuation of avoiding cardiac compared to respira-
tory disease episodes is driven mainly by the much higher
proportion of cardiac conditions requiring admission to
hospital, critical care, and invasive procedures [29]. Valu-
ation for emergency department visits for both types of
conditions includes cost of treatment related to hospital
admission for those patients who were ultimately admit-
ted. Because cardiac patients were much more likely to be
admitted, this is reflected in a much larger cost of treat-
ment value for cardiac compared to respiratory emergency
department visits. While this would result in double
counting of benefits where both hospital admissions and
emergency visits are assessed and monetized in a benefits
analysis, this approach was considered appropriate be-
cause concentration-response relationships for air pollu-
tion and emergency department visits are based on all
those who visit the emergency department, including
those who are ultimately admitted to hospital. Where
both types of outcomes are being considered in benefits
analysis, double counting can be avoided by using con-
centration-response relationships for emergency depart-
ment visits to capture both types of effects, either by using
relationships taken directly from epidemiological studies
Table 4: Parameter estimates for cost of treatment model
Variable 
Name
Variable Description Parameter Estimate ($) Standard Error ($)
VCOT = α + βASAS + βCHFCHF + βDD + βCCCC + βNCCNCC + βAS*DAS*D + βRI*DRI*D + βMIA*DMIA*D + βRI*CCRI*CC + βDYS*CCDYS*CC
Intercept Intercept term 348.58 90.71
AS Dummy variable for diagnosis of asthma (0,1) 440.33 125.97
CHF Dummy variable for diagnosis of congestive heart failure (0,1) 1680.09 406.92
D Total duration of disease episode (days) 31.70 7.85
CC Dummy variable for admission to hospital in critical care unit (0,1) 4530.36 176.20
NCC Dummy variable for admission to hospital in non-critical care unit (0,1) 1977.94 163.67
AS*D Interaction term (see variable definitions above) -27.71 9.17
RI*D Interaction term where RI is a dummy variable for diagnosis of respiratory infec-
tion (0,1)
-29.02 8.07
MIA*D Interaction term where MIA is a dummy variable for diagnosis of myocardial inf-
arction/angina (0,1)
-30.54 14.50
RI*CC Interaction term (see variable definitions above) -1544.58 538.12
DYS*CC Interaction term where DYS is a dummy variable for diagnosis of dysrhythmia 
(0,1)
-2402.73 906.97
AS*NCC Interaction term (see variable definitions above) -431.01 272.89
MIA*NCC Interaction term (see variable definitions above) 1180.79 301.74
CHF*NCC Interaction term (see variable definitions above) -2158.82 539.88Environmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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of air pollution and emergency department visits, or scal-
ing up concentration response relationships from studies
of hospital admissions, based on the expected ratio be-
tween hospital admissions and emergency department
visits [1]. (See illustrative example below.)
Comparison with existing estimates
We present a comparison of our estimates with those from
earlier studies [1–7,43,44] in figures 1,2,3 and Table 6
(see additional file 1). We have categorized estimates
from earlier studies based on the authors' description of
the health state, and the primary sources cited. It is
difficult to make precise comparisons, however, because
many other studies do not specify the level of activity lim-
itation associated with the condition being valued, and
our estimates pertaining to emergency department visits
differ from earlier estimates in that they also capture costs
for those patients who were ultimately admitted.
Nonetheless, in general, our estimates are comparable in
magnitude to those from earlier studies in this area. A pri-
ori, we might have expected that our more comprehensive
approach would have resulted in somewhat higher esti-
mates compared to earlier studies. We observed that valu-
ation estimates for the less severe outcomes were sensitive
to specification of severity level, such that specifying a
higher level of severity produced estimates at the higher
end of those reported in earlier studies. It is also possible
that in the context of the less severe outcomes which are
associated with relatively low valuation, our approach,
though more comprehensive, adds only small increments
which do not result in a substantial change in magnitude
of the overall estimate
Our estimates for hospital admissions are less than in
most earlier studies. With respect to the cost of treatment
component for this outcome, compared to the Anis et al.
study [27], two studies based on U.S. data reported higher
costs for pneumonia [45] and congestive heart failure
[46], while another from Canada revealed similar costs for
asthma hospital admissions [[47], personal communica-
tion, Dr. W. Ungar, November 2002]. Estimates from the
U.K. were also similar to those derived here [6]. The esti-
mates advanced by Chestnut et al. [1], though developed
for Canada, are also based partially on U.S. data [48].
These findings may reflect true systematic differences in
costs of treatment in the U.S. compared to Canada and the
U.K.. It has been documented that intensity of care for
some conditions is greater in the United States than Can-
ada [49], and that administrative/overhead costs are
significantly higher in the U.S. than in Canada in relation
to the multiple versus single payer systems in the two
countries [50,51]. Given that the ratios we observed for
total value to COI were generally similar to (or indeed at
the lower end of) those reported previously [1,4,15–17],
this indicates that the component of valuation related to
avoided pain and suffering and averting expenditures is
also lower than earlier estimates. This may suggest that
WTP to avoid health outcomes associated with significant
health care costs may be lower in the context of a publicly
funded universal health care system, possibly because of
lower perceived risks of catastrophic financial conse-
quences. Thus it appears that in the case of hospital ad-
missions, the impact of our more comprehensive
approach to valuation is overshadowed by lower costs of
treatment in Canada compared to the U.S., which has
been the predominant source of earlier such estimates.
Table 5: Valuation estimatesa and ratio of total value to cost of illness, by endpoint and component
Endpoint Cost of 
Treatment (CoT)
Lost 
Productivity (LP)
Pain, Suffering and Averting 
Expenditures
Total Total Value/
(CoT + LP)
In Hospital Out of
 Hospital
Point
 Estimate
95% CI
Respiratory Hospital 
Admission
$2,800 $300 $670 $410 $4,200 ($3,400, 
$5,000)
1.3
Cardiac Hospital Admission $3,800 $270 $760 $340 $5,200 ($4,000, 
$6,400)
1.3
Respiratory Emergency 
Department Visit
$930 $160 $430 $520 $2,000 ($1,700, 
$2,500)
1.9
Cardiac Emergency 
Department Visit
$3,200 $210 $680 $330 $4,400 ($3,300, 
$5,600)
1.3
Restricted Activity Day $25 $23 $48 ($13, $82) 1.9
Asthma Symptom Day $12 $16 $28 ($11, $71) 2.3
Acute Respiratory 
Symptom Day
$12 $1 $13 ($0, $28) 1.1
aestimates rounded to two significant figuresEnvironmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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Limitations of our approach
While we believe our results represent an advance over
earlier estimates, there are several limitations which could
be addressed in future work in this area. The model we
employed for stated preference values was non-linear with
respect to duration of the illness episode, implying dimin-
ishing marginal utility for reduced morbidity with respect
to duration [28]. However, we assumed simple additivity
of the individual blocks of time constituting each segment
of activity restriction of varying severity in the context of
an illness episode. This was necessitated by the finding in
the context of the original stated preference survey, that
presenting individuals with illness episode scenarios in-
volving an evolution of level of activity restriction was
overly burdensome for respondents. Our assumption of
simple additivity is likely to lead to overestimates of total
value relative to the observation in the original study of
diminishing marginal utility with respect to duration [28].
The extent of bias requires further empirical evaluation.
Additional development work would be needed to deter-
mine how best to communicate this information to re-
spondents in a straightforward yet accurate way, and to
elicit valuation information appropriately.
Our analysis relied on data from two studies carried out in
single centres (Saint John and Toronto). While we found
that our results were not sensitive to demographic and
health status differences between the original stated pref-
erence survey sample and Canada as a whole, repeating
the survey in multiple centres would nevertheless be desir-
able, as would collecting illness episode, cost of
treatment, and stated preference information from the
same sample of respondents.
Response rate is a potential concern for both the cost of
illness study and the stated preference survey. Response
rates to the emergency department follow-up survey were
greater than 80% for individuals with asthma and respira-
tory infections, but only 50% and 67% for those with
COPD and cardiac conditions respectively. Those with
cardiac conditions who completed follow-up interviews
were younger (and possibly healthier) than those who did
not [29]. Cost of treatment estimates may therefore be
Figure 1
Comparison of valuation estimates for hospital admissions and emergency department visits with earlier studies. Legend: 
Labels denote reference number. Open symbols denote estimates from the present study. See Table 6  (additional file 1) for 
additional details on individual estimates.Environmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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conservative relative to a fully representative population
of patients of all degrees of severity. Lower and upper
bounds on the response rate for the stated preference
survey were 22 and 63 percent, assuming that respectively
all or none of the telephone numbers which could not be
contacted or verified as households were included in the
denominator [30]. Of prospective subjects who complet-
ed the screening telephone survey, 45 percent agreed to
take the in-person survey, while 72 percent of those who
scheduled an appointment actually completed the in-per-
son survey [30]. Thus, a substantial portion of the sample
did not complete the in-person survey. While a low
response rate would raise concerns about the representa-
tiveness of the sample, no major differences were ob-
served with respect to demographic characteristics or
health status characteristics which were found to influ-
ence WTP in this study.
An additional potential limitation of our results is the
possibility of double counting of out of pocket expendi-
tures, which could potentially have been captured by both
the cost of treatment study and the stated preference will-
ingness to pay study. Ungar et al. [47] found that out of
pocket expenses accounted for only 1 per cent of annual
per patient treatment costs for asthma, which suggests that
this is probably not an important issue.
An illustrative example
We illustrate the application of our approach by examin-
ing the benefits associated with reduced cardiorespiratory
emergency department visits and hospital admissions at-
tributable to the decline in particulate sulfate concentra-
tions observed in Toronto from the mid 1980s to the late
1990s. Average particulate sulfate concentrations in the
Toronto Census Metropolitan Area (CMA) declined from
5.0  µg/m3 (1984–1986 average) to 3.8 µg/m3  (1997–
1999 average) during this period. We estimated the bene-
fits in 2000 when the estimated population was 4.771
million, using results from an epidemiological study ex-
amining the association of air pollution with hospital ad-
missions for respiratory and cardiac disease in southern
Ontario [22]. We used this study rather than more recent
work because of recently identified problems with the sta-
tistical analysis software which has become the standard
Figure 2
Comparison of valuation estimates for restricted activity days and asthma symptom days with earlier studies. Legend: Labels 
denote reference number. Open symbols denote estimates from the present study. See Table 6 (additional file 1) for additional 
details on individual estimates.Environmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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over the past 5 to 6 years in the analysis of time-series data
[52], the full impact of which is still being evaluated. The
rates of admission reported in the study translate into
25,000 cardiac and 28,000 respiratory hospital admis-
sions in the Toronto CMA in 2000. Applying the propor-
tion of cardiac and respiratory emergency department
visits resulting in admission to hospital from the Saint
John study (76% and 20%), [29,33] the numbers of
hospital admissions correspond to 33,000 cardiac and
140,000 respiratory emergency department visits in 2000.
Based on this study, we estimated that a 1.2 µg/m3 de-
crease in sulfate concentration would respectively result in
a 0.30 % decrease in cardiac hospital admissions/emer-
gency department visits (95% CI 0.16–0.45) and a 0.32%
decrease in respiratory hospital admissions/emergency
department visits (95% CI 0.21–0.43), accounting for the
simultaneous effects of ozone and temperature. The pro-
portional reduction is the same for admissions and emer-
gency visits because in this example the concentration
response function is simply scaled based on the relative
frequency of the two types of outcome.
We estimated the benefits of the observed changes in sul-
fate concentration, specifying both the concentration re-
sponse relationship and the valuation estimates generated
above as normal distributions based on the point estimate
and standard error, using a Monte Carlo simulation with
1,000 iterations implemented using Analytica software
[53]. It was estimated that the benefits of reduced
emergency department visits for respiratory and cardiac
disease were respectively $910,000 and $440,000, while
the benefits of reduced respiratory and cardiac hospital
admissions were $380,000 and $390,000. However, be-
cause essentially all non-elective hospital admissions oc-
cur through the emergency department, and the valuation
estimates generated above for emergency department vis-
its reflect the probability and valuation of subsequent ad-
mission to hospital, the total benefits are simply the sum
of those related to emergency department visits or $1.4
million (95% CI 0.91–1.8 million). We emphasize that
this estimate does not reflect the much larger benefits at-
tributable to reduced mortality and chronic morbidity.
Figure 3
Comparison of valuation estimates for acute respiratory symptom days with earlier studies. Legend: Labels denote reference 
number. Open symbols denote estimates from the present study. See Table 6 (additional file 1) for additional details on individ-
ual estimates.Environmental Health: A Global Access Science Source 2002, 1 http://www.ehjournal.net/content/1/1/7
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Conclusions
We believe our overall approach addresses a number of
the limitations of the current literature and is widely ap-
plicable to future assessments of the benefits of improved
air quality. However, because we have noted potentially
significant differences between the U.S. and Canada in
valuation of certain outcomes, the revised morbidity val-
uation estimates presented here are most suitable for use
in assessing the benefits of air pollution mitigation initia-
tives in Canada. We recommend employing sensitivity
analyses with respect to severity of activity limitation, for
those health outcomes where we observed significant sen-
sitivity to this factor.
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